Sex, racial, ethnic, and geographical disparities in major adverse cardiovascular outcome of glucagon-like peptide-1 receptor agonists among patients with and without diabetes mellitus: A meta-analysis of placebo-controlled randomized controlled trials

被引:1
作者
Rivera, Frederick Berro [1 ]
Bantayan, Nathan Ross B. [2 ]
Aparece, John Paul [3 ]
Cruz, Linnaeus Louisse A. [2 ]
Magallong, John Vincent [3 ]
Pine, Polyn Luz [4 ]
Idian-Javier, Anne Mira Nicca [4 ]
Lumbang, Grace Nooriza O. [5 ]
Lerma, Edgar, V [6 ]
Lara-Breitinger, Kyla M. [7 ]
Gulati, Martha [8 ]
Vijayaraghavan, Krishnaswami [9 ]
机构
[1] Lincoln Med Ctr, Dept Med, New York, NY USA
[2] Univ Philippines, Coll Med, Manila, Philippines
[3] Texas Tech Univ, Dept Med, Hlth Sci Ctr, El Paso, TX USA
[4] AteneoSch Med & Publ Hlth, Pasig, Philippines
[5] Cebu Inst Med, Dept Med, Cebu, Philippines
[6] Univ Illinois, Chicago Coll Med, Sect Nephrol, Chicago, IL USA
[7] Mayo Clin, Dept Cardiovasc Med, Rochester, MN USA
[8] Cedars Sinai Smidt Heart Inst, Barbra Streisand Womens Heart Ctr, Dept Cardiol, Los Angeles, CA USA
[9] Univ Arizona, 475 N 5th St, Phoenix, AZ 85004 USA
关键词
Glucagon-like peptide 1 receptor agonists; GLP-1RA; Cardiovascular outcomes; MACE; Sex; Ethnic; Geographic; Disparities; ASIANS SIMILARITIES; EXENATIDE; LIRAGLUTIDE; POPULATIONS; SECRETION; EFFICACY; WOMEN;
D O I
10.1016/j.jacl.2024.03.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been pivotal in the management of type 2 diabetes mellitus (T2DM) and in the reduction of major adverse cardiovascular events (MACE). Notably, large cardiovascular outcomes trials (CVOTs) demonstrate significant disparities in inclusion, based on sex, race, ethnicity, and geographical regions. OBJECTIVES: We examined the impact of GLP-1RA on MACE in patients with or without T2DM, based on sex, race, ethnicity, and geography. METHODS: A literature search for placebo controlled randomized controlled trials on GLP-1RA treatment was conducted. Thorough data extraction and quality assessment were carried out, focusing on key outcome, and ensuring a robust statistical analysis using a random effects model to calculate log odds ratio (OR) with 95% confidence intervals (CIs). RESULTS: A total of 8 CVOTs comprising 71,616 patients were included. Compared with placebo, GLP-1RAs significantly reduced MACE in both sexes (females: logOR-0.19, (95% CI,-0.28 to-0.10), p < 0.01) versus (males: logOR-0.17, (95% CI,-0.23 to-0.10), p < 0.01), (p interaction NS), and among Asians (logOR-34 (95% CI,-0.53 to-0.15), p < 0.01), and Whites (logOR-17 (95% CI,-0.25 to-0.09), p < 0.01), with no difference in MACE among Blacks and Hispanics. Odds of MACE were also reduced in Asia (logOR-31 (95% CI,-0.50 to-0.11), p < 0.01), and Europe (logOR-27 (95% CI,-0.40 to-0.13), p < 0.01), but there was no statistical difference in MACE in North America and Latin America. CONCLUSION: Significant reductions in MACE with GLP-1RA treatment were demonstrated between both sexes and across certain ethnicities and certain geographical regions. (c) 2024 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页码:e588 / e601
页数:14
相关论文
共 51 条
[1]  
Berro MDMD Rivera Frederick, 2023, Sex Differences in Cardiovascular Outcomes and Cholesterol-Lowering Efficacy of PCSK9 Inhibitors: systematic Review and Meta-Analysis
[2]   Trends in recruitment of women and reporting of sex differences in large-scale published randomized controlled trials in stroke [J].
Carcel, Cheryl ;
Woodward, Mark ;
Balicki, Grace ;
Koroneos, Georgia Louise ;
de Sousa, Diana Aguiar ;
Cordonnier, Charlotte ;
Lukaszyk, Caroline ;
Thompson, Kelly ;
Wang, Xia ;
Davies, Leo ;
Bassi, Meenakshi ;
Anderson, Craig S. ;
Peters, Sanne A. E. ;
Sandset, Else Charlotte .
INTERNATIONAL JOURNAL OF STROKE, 2019, 14 (09) :931-938
[3]   Incretin physiology and pathophysiology from an Asian perspective [J].
Cho, Young Min .
JOURNAL OF DIABETES INVESTIGATION, 2015, 6 (05) :495-507
[4]   Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials [J].
Cotter, Gad ;
Davison, Beth A. ;
Edwards, Christopher ;
Senger, Stefanie ;
Teerlink, John R. ;
Zannad, Faiez ;
Nielsen, Olav Wendelboe ;
Metra, Marco ;
Mebazaa, Alexandre ;
Chioncel, Ovidiu ;
Greenberg, Barry H. ;
Maggioni, Aldo P. ;
Ertl, Georg ;
Sato, Naoki ;
Cohen-Solal, Alain .
AMERICAN HEART JOURNAL, 2021, 240 :73-80
[5]   Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis [J].
D'Andrea, Elvira ;
Kesselheim, Aaron S. ;
Franklin, Jessica M. ;
Jung, Emily H. ;
Hey, Spencer Phillips ;
Patorno, Elisabetta .
CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
[6]   Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials [J].
Dawed, Adem Y. ;
Mari, Andrea ;
Brown, Andrew ;
McDonald, Timothy J. ;
Li, Lin ;
Wang, Shuaicheng ;
Hong, Mun-Gwan ;
Sharma, Sapna ;
Robertson, Neil R. ;
Mahajan, Anubha ;
Wang, Xuan ;
Walker, Mark ;
Gough, Stephen ;
Hart, Leen M. 't ;
Zhou, Kaixin ;
Forgie, Ian ;
Ruetten, Hartmut ;
Pavo, Imre ;
Bhatnagar, Pallav ;
Jones, Angus G. ;
Pearson, Ewan R. ;
DIRECT consortium, for the D. I. R. E. C. T. consortium .
LANCET DIABETES & ENDOCRINOLOGY, 2023, 11 (01) :33-41
[7]   Geographic differences in outcomes in outpatients with established atherothrombotic disease: results from the REACH Registry [J].
Ducrocq, G. ;
Bhatt, D. L. ;
Labreuche, J. ;
Corbalan, R. ;
Porath, A. ;
Gao, R. ;
Panchenko, E. ;
Liau, C. S. ;
Ikeda, Y. ;
Goto, S. ;
Amarenco, P. ;
Steg, P. G. .
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2014, 21 (12) :1509-1516
[8]   Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US [J].
Eberly, Lauren A. ;
Yang, Lin ;
Essien, Utibe R. ;
Eneanya, Nwamaka D. ;
Julien, Howard M. ;
Luo, Jing ;
Nathan, Ashwin S. ;
Khatana, Sameed Ahmed M. ;
Dayoub, Elias J. ;
Fanaroff, Alexander C. ;
Giri, Jay ;
Groeneveld, Peter W. ;
Adusumalli, Srinath .
JAMA HEALTH FORUM, 2021, 2 (12) :E214182
[9]   Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023 [J].
ElSayed, Nuha A. ;
Aleppo, Grazia ;
Aroda, Vanita R. ;
Bannuru, Raveendhara R. ;
Brown, Florence M. ;
Bruemmer, Dennis ;
Collins, Billy S. ;
Hilliard, Marisa E. ;
Isaacs, Diana ;
Johnson, Eric L. ;
Kahan, Scott ;
Khunti, Kamlesh ;
Leon, Jose ;
Lyons, Sarah K. ;
Perry, Mary Lou ;
Prahalad, Priya ;
Pratley, Richard E. ;
Seley, Jane Jeffrie ;
Stanton, Robert C. ;
Gabbay, Robert A. .
DIABETES CARE, 2023, 46 :S140-S157
[10]   Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes - a Danish nationwide observational study [J].
Falkentoft, Alexander C. ;
Andersen, Julie ;
Malik, Mariam Elmegaard ;
Selmer, Christian ;
Gaede, Peter Haulund ;
Staehr, Peter Bisgaard ;
Hlatky, Mark A. ;
Fosbol, Emil ;
Kober, Lars ;
Torp-Pedersen, Christian ;
Gislason, Gunnar H. ;
Gerds, Thomas Alexander ;
Schou, Morten ;
Bruun, Niels E. ;
Ruwald, Anne-Christine .
LANCET REGIONAL HEALTH-EUROPE, 2022, 14